New anticancer vaccine shows early success in targeting neuroblastoma (opens in new tab)

A new study from RCSI University of Medicine and Health Sciences demonstrates a novel approach in anticancer vaccine development. The results, published in Molecular Therapy Oncology, present the first preclinical evidence showing the efficacy of an mRNA vaccine in targeting neuroblastoma, the deadliest childhood cancer.